Cargando…

Serum Metabolomic Biomarkers of Dementia

Aims: This study compared serum metabolites of demented patients (Alzheimer's disease and vascular dementia) and controls, and explored serum metabolite profiles of nondemented individuals 5 years preceding the diagnosis. Methods: Cognitively healthy participants were followed up for 5-20 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Mousavi, Malahat, Jonsson, Pär, Antti, Henrik, Adolfsson, Rolf, Nordin, Annelie, Bergdahl, Jan, Eriksson, Kåre, Moritz, Thomas, Nilsson, Lars-Göran, Nyberg, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132238/
https://www.ncbi.nlm.nih.gov/pubmed/25177334
http://dx.doi.org/10.1159/000364816
Descripción
Sumario:Aims: This study compared serum metabolites of demented patients (Alzheimer's disease and vascular dementia) and controls, and explored serum metabolite profiles of nondemented individuals 5 years preceding the diagnosis. Methods: Cognitively healthy participants were followed up for 5-20 years. Cognitive assessment, serum sampling, and diagnosis were completed every 5 years. Multivariate analyses were conducted on the metabolite profiles generated by gas chromatography/time-of-flight mass spectrometry. Results: A significant group separation was found between demented patients and controls, and between incident cases and controls. Metabolites that contributed in both analyses were 3,4-dihydroxybutanoic acid, docosapentaenoic acid, and uric acid. Conclusions: Serum metabolite profiles are altered in demented patients, and detectable up to 5 years preceding the diagnosis. Blood sampling can make an important contribution to the early prediction of conversion to dementia.